We are live on ! Find out more
NRSN icon

NeuroSense Therapeutics
NRSN

7 hedge funds and large institutions have $733K invested in NeuroSense Therapeutics in 2022 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 0 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

6% more capital invested

Capital invested by funds: $694K → $733K (+$39K)

0.32% more ownership

Funds ownership: 1.54% → 1.86% (+0.32%)

22% less funds holding

Funds holding: 9 → 7 (-2)

40% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 5

Holders
7
Holders Change
-2
Holders Change %
-22.22%
% of All Funds
0.12%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
4
Reduced
–
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citigroup
Citigroup
New York
+$94.2K
2
Vanguard Personalized Indexing Management
Vanguard Personalized Indexing Management
California
+$75.1K
3
Jane Street
Jane Street
New York
+$63.9K
4
Millennium Management
Millennium Management
New York
+$38.4K
5
UBS Group
UBS Group
Switzerland
+$21.9K

Top Sellers

Rank Fund Capital Flow
1
IC
Ikarian Capital
Texas
-$397K
2
Bank of Montreal
Bank of Montreal
Ontario, Canada
-$65K
3
BFM
Boothbay Fund Management
New York
-$48K
4
FIA
FNY Investment Advisers
New York
-$3K

NRSN Hedge Fund Activity: Q2 2022 in Review

7 of the 5,960 institutional investors tracked by Wall St. Rank reported a position in NeuroSense Therapeutics (NRSN) for Q2 2022, worth a combined $733K — up 5.6% from $694K a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of NRSN and 3 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 4 added.

The largest buyer was Citigroup, adding an estimated $94.2K. The largest seller was Ikarian Capital, exiting entirely with an estimated $397K sold.

  • 7 institutional investors held NeuroSense Therapeutics (NRSN) as of Q2 2022, down from 9 in Q1 2022.
  • Funds reported $733K of NeuroSense Therapeutics stock for Q2 2022, up 5.6% quarter-over-quarter.
  • 3 funds opened new NeuroSense Therapeutics positions in Q2 2022 and 5 closed out, a net change of -2 holders.
  • The largest NeuroSense Therapeutics buyer in Q2 2022 was Citigroup, an estimated $94.2K added.
  • The largest NeuroSense Therapeutics seller in Q2 2022 was Ikarian Capital, an estimated $397K sold.

Based on aggregated 13F filings for Q2 2022.